EUVIMEDEUVIMED entdecken
Crossref

What are the benefits and harms of erythropoiesis-stimulating agents (ESAs) (erythropoietin or darbepoetin alfa) for preterm or low-birthweight infants?

Adarsh Gupta

Cochrane Clinical Answers · 15.07.2026

DOI: 10.1002/cca.4827 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cochrane Clinical Answers, online erschienen am 15.07.2026. Verfasst von Adarsh Gupta. Die Arbeit nennt 18 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Gupta, A. (2026). What are the benefits and harms of erythropoiesis-stimulating agents (ESAs) (erythropoietin or darbepoetin alfa) for preterm or low-birthweight infants?. Cochrane Clinical Answers. https://doi.org/10.1002/cca.4827

Vancouver

Gupta A. What are the benefits and harms of erythropoiesis-stimulating agents (ESAs) (erythropoietin or darbepoetin alfa) for preterm or low-birthweight infants?. Cochrane Clinical Answers. 2026. doi:10.1002/cca.4827

BibTeX
@article{Gupta2026,
  author = {Gupta, Adarsh},
  title = {What are the benefits and harms of erythropoiesis-stimulating agents (ESAs) (erythropoietin or darbepoetin alfa) for preterm or low-birthweight infants?},
  journal = {Cochrane Clinical Answers},
  year = {2026},
  doi = {10.1002/cca.4827}
}
Kostenlos starten →